vimarsana.com

Page 17 - குறைந்தபட்சம் ஆக்கிரமிப்பு அறுவை சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Centessa Pharma s IPO brings in $330M for its new model of drug R&D

Three life science companies went public in the last full week of May. The biggest IPO belonged to Centessa Pharmaceuticals, a company that raised $330 million to support its unconventional but not unprecedented approach to drug R&D.

FDA faces big questions as it takes a closer look at AI regulations

Bassett Healthcare Network outsources IT, RCM operations to Optum

MedCity News Bassett Healthcare Network outsources IT, RCM operations to Optum The New York-based rural health system has entered into a collaboration to outsource its IT and revenue cycle management operations to Optum. Further, about 500 Bassett employees, who currently perform those functions, will be given the opportunity to transition to Optum. Shares0 Per a new strategic collaboration, Optum will take over information technology and revenue cycle management operations for Cooperstown, New York-based Bassett Healthcare Network. The organizations announced the collaboration last week, stating that Eden Prairie, Minnesota-based Optum will provide the health system with a range of services. These include tools and strategies that support the patient journey, from scheduling to payment; new analytic capabilities; modernized revenue cycle processes; and IT strategies that include enhancing infrastructure and network security across all five hospitals in Bassett’s network.

After getting FDA clearance for video game therapeutic, Akili faces next level: insurance coverage

Akili Interactive, a digital health company that got FDA clearance last year for its video game as treatment for ADHD, recently brought in $160 million in funding. It plans to use the funds to ramp up coverage of its flagship treatment and to develop digital treatments for other cognitive conditions. 

Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer

FDA approval of Amgen drug sotorasib (Lumakras) makes the small molecule the first compound authorized by the regulator for treating cancers characterized by a KRAS G12C mutation. Mutated KRAS proteins had long been regarded "undruggable" targets.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.